Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

Background and Rationale:

Optimal nutrition during labor for patients with insulin-treated diabetes in pregnancy remains poorly defined. While current guidelines support clear liquid intake during labor, the metabolic effects of different nutritional strategies-particularly high-protein supplementation-have not been studied. Maintaining stable maternal glucose levels during labor is essential to reducing neonatal complications, including hypoglycemia. However, standard clear liquids may cause glucose excursions, while prolonged fasting may contribute to maternal fatigue and metabolic stress.

Continuous glucose monitoring (CGM) technology provides real-time assessment of glucose patterns during labor, offering a novel opportunity to evaluate how targeted nutritional interventions influence maternal glycemic stability. Recent evidence suggests that maternal time above glucose target range during labor is associated with neonatal hypoglycemia, yet no studies have examined whether protein-based oral supplementation can improve intrapartum glucose control compared to standard clear liquids.

Study Objectives:

This pilot randomized controlled trial evaluates the feasibility and metabolic impact of high-protein oral supplementation during labor in patients with insulin-treated gestational or type 2 diabetes undergoing induction of labor. The study aims to:

1. Assess feasibility and acceptability of implementing a CGM-guided intrapartum nutritional protocol 2. Compare CGM-derived glycemic metrics (including percent time above range \>110 mg/dL, time in range, and glycemic excursions) between high-protein supplementation and standard clear liquids 3. Explore associations with maternal experience (fatigue, birth satisfaction) and neonatal outcomes

Study Design:

Sixty participants with insulin-treated gestational diabetes (GDM A2) or type 2 diabetes will be randomized 1:1 to receive either high-protein nutritional supplements (30g protein, 0g carbohydrate) every 4 hours during labor or standard institutional clear liquid diet. All participants will wear a blinded CGM (Abbott Freestyle Libre) from admission through delivery and for up to 7 days postpartum. The primary outcome is percent time above glucose range (\>110 mg/dL) during labor. Secondary outcomes include other CGM metrics, maternal fatigue and satisfaction scores, labor outcomes, and neonatal hypoglycemia.

Significance:

This pilot study will generate critical preliminary data on the metabolic effects, patient-centered outcomes, and feasibility of high-protein intrapartum supplementation, informing the design of future larger trials to optimize evidence-based nutritional management during labor for patients with insulin-treated diabetes.

• Time in Range [Срок оценки: From admission to delivery (expected ≤72 hours)]
• Glycemic Variability [Срок оценки: From admission to delivery (expected ≤72 hours)]
• Hyperglycemic Excursions [Срок оценки: From admission to delivery (expected ≤72 hours)]
• Hypoglycemic Events [Срок оценки: From admission to delivery (expected ≤72 hours)]
• Total Insulin Use During Labor [Срок оценки: From admission to delivery (expected ≤72 hours)]
• Maternal Fatigue Score (VAS) [Срок оценки: Admission and every 4 hours until delivery (expected ≤72 hours)]
• Labor Agentry Scale Score (LAS) [Срок оценки: 24-48 hours postpartum]
• Birth Satisfaction Scale-Revised Score [Срок оценки: 24-48 hours postpartum]
• Maternal Emesis [Срок оценки: From admission to delivery (expected ≤72 hours)]
• Mode of Delivery [Срок оценки: At delivery]
• Neonatal Hypoglycemia [Срок оценки: First 24 hours of life]
• Neonatal Intensive Care Unit (NICU) Admission [Срок оценки: From birth through hospital discharge (expected ≤28 days)]